Pfizer Inc (MIL:1PFE)
€ 24.625 -0.215 (-0.87%) Market Cap: 139.23 Bil Enterprise Value: 192.39 Bil PE Ratio: 35.39 PB Ratio: 1.61 GF Score: 64/100

Pfizer Inc Analyst and Investor Call to Discuss Etrasimod Data Presentation at Digestive Disease Week Call Transcript

May 24, 2022 / 08:00PM GMT

May 24, 2022 / 08:00PM GMT
Presentation at Digestive Disease Week Call
May 24, 2022 / 08:00PM GMT

=====================
Corporate Participants
=====================
* Christopher J. Stevo
Pfizer Inc. - Senior VP & Chief IR Officer
* Michael Corbo
Pfizer Inc. - Chief Development Officer, Inflammation & Immunology
* Michael S. Vincent
Pfizer Inc. - Senior VP and Chief Scientific Officer, Inflammation & Immunology
* Mike Gladstone
Pfizer Inc. - Global President, Inflammation & Immunology
* Sheldon Sloan
Arena Pharmaceuticals Inc. - Vice President, Etrasimod UC Team Lead

=====================
Conference Call Participants
=====================
* Brian Tsang
Wolfe Research, LLC - Research Analyst
* Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
* Evan David Seigerman
BMO Capital Markets Equity Research - MD & Senior BioPharma Research Analyst
* Geoffrey Christopher Meacham
BofA Securities, Research Division - Research Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot